CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

My Organizations' Clinical Trials

Showing 50 of 232 entries

View as:

Study of VX-770 on Desipramine

Phase: N/A Priority: Normal

NCT ID: NCT01153542 Org: User:

Start: 06/30/10 End: 08/31/10 Due: 08/31/11

A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin

Phase: N/A Priority: Normal

NCT ID: NCT05541471 Org: User:

Start: 09/22/22 End: 04/28/23 Due: 04/28/24

A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del

Phase: N/A Priority: Normal

NCT ID: NCT03625466 Org: User:

Start: 08/10/18 End: 10/07/21 Due: 10/07/22

Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation

Phase: N/A Priority: Normal

NCT ID: NCT01705145 Org: User:

Start: 01/31/13 End: 03/31/14 Due: 03/31/15

A Study to Evaluate the Effect of Food on the Pharmacokinetics of VX-548

Phase: N/A Priority: Normal

NCT ID: NCT05851157 Org: User:

Start: 05/03/23 End: 11/08/23 Due: 11/08/24

A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

Phase: N/A Priority: Normal

NCT ID: NCT05033080 Org: User:

Start: 09/14/21 End: 11/21/23 Due: 11/21/24

Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Mild or Moderate Hepatic Impairment

Phase: N/A Priority: Normal

NCT ID: NCT05560464 Org: User:

Start: 10/14/22 End: 07/24/23 Due: 07/24/24

Study of VX-985 in Subjects With Chronic Hepatitis C

Phase: N/A Priority: Normal

NCT ID: NCT01144936 Org: User:

Start: 06/30/10 End: 10/31/10 Due: 10/31/11

A Phase 1 Dose Escalation Study of VX-973 in Healthy Adults

Phase: N/A Priority: Normal

NCT ID: NCT05866055 Org: User:

Start: 05/10/23 End: 04/04/24 Due: 04/04/25

Phase 1 PK Interaction Study Between VX-509 and Prednisone or Methylprednisolone in Healthy Male Subjects

Phase: N/A Priority: Normal

NCT ID: NCT01886209 Org: User:

Start: 06/30/13 End: 08/31/13 Due: 08/31/14

Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765

Phase: N/A Priority: Normal

NCT ID: NCT00205465 Org: User:

Start: 12/31/04 End: 09/30/05 Due: 09/30/06

Virology Follow up Study in Subjects Previously Treated With Telaprevir

Phase: N/A Priority: Normal

NCT ID: NCT00916474 Org: User:

Start: 06/30/09 End: 12/31/13 Due: 12/31/14

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548

Phase: N/A Priority: Normal

NCT ID: NCT05455502 Org: User:

Start: 07/13/22 End: 09/17/22 Due: 09/17/23

A Phase 1, First-in-human Study of VX-668

Phase: N/A Priority: Normal

NCT ID: NCT05727800 Org: User:

Start: 02/08/23 End: 02/13/24 Due: 02/13/25

A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy Participants

Phase: N/A Priority: Normal

NCT ID: NCT05818852 Org: User:

Start: 04/12/23 End: 06/28/23 Due: 06/28/24

A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants

Phase: N/A Priority: Normal

NCT ID: NCT05518734 Org: User:

Start: 09/17/22 End: 03/07/23 Due: 03/07/24

Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study)

Phase: N/A Priority: Normal

NCT ID: NCT02445053 Org: User:

Start: 04/30/15 End: 10/31/20 Due: 10/31/21

A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose

Phase: N/A Priority: Normal

NCT ID: NCT06886269 Org: User:

Start: 03/21/25 End: 05/17/25 Due: 05/17/26

An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis

Phase: N/A Priority: Normal

NCT ID: NCT01863238 Org: User:

Start: 05/31/13 End: 05/31/16 Due: 05/31/17

Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

Phase: N/A Priority: Normal

NCT ID: NCT05477563 Org: User:

Start: 08/02/22 End: 06/09/27 Due: 06/09/28

Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation

Phase: N/A Priority: Normal

NCT ID: NCT01161537 Org: User:

Start: 10/31/10 End: 02/28/13 Due: 02/28/14

A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using Wearable Technology in Cystic Fibrosis

Phase: N/A Priority: Normal

NCT ID: NCT04923464 Org: User:

Start: 06/30/21 End: 12/20/21 Due: 12/20/22

A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)

Phase: N/A Priority: Normal

NCT ID: NCT04599465 Org: User:

Start: 01/15/21 End: 07/14/22 Due: 07/14/23

Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis

Phase: N/A Priority: Normal

NCT ID: NCT03278314 Org: User:

Start: - End: - Due: -

Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection

Phase: N/A Priority: Normal

NCT ID: NCT00623649 Org: User:

Start: 11/30/07 End: 10/31/08 Due: 10/31/09

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Study of VX-770 on Desipramine	NCT01153542	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2010-06-30	2010-08-31	2011-08-31	-	-	2025-07-14
A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin	NCT05541471	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2022-09-22	2023-04-28	2024-04-28	-	-	2025-07-14
A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del	NCT03625466	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2018-08-10	2021-10-07	2022-10-07	-	-	2025-07-14
Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation	NCT01705145	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2013-01-31	2014-03-31	2015-03-31	-	-	2025-07-14
A Study to Evaluate the Effect of Food on the Pharmacokinetics of VX-548	NCT05851157	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2023-05-03	2023-11-08	2024-11-08	-	-	2025-07-14
A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)	NCT05033080	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2021-09-14	2023-11-21	2024-11-21	-	-	2025-07-14
Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Mild or Moderate Hepatic Impairment	NCT05560464	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2022-10-14	2023-07-24	2024-07-24	-	-	2025-07-14
Study of VX-985 in Subjects With Chronic Hepatitis C	NCT01144936	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2010-06-30	2010-10-31	2011-10-31	-	-	2025-07-14
A Phase 1 Dose Escalation Study of VX-973 in Healthy Adults	NCT05866055	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2023-05-10	2024-04-04	2025-04-04	-	-	2025-07-14
Phase 1 PK Interaction Study Between VX-509 and Prednisone or Methylprednisolone in Healthy Male Subjects	NCT01886209	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2013-06-30	2013-08-31	2014-08-31	-	-	2025-07-14
Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765	NCT00205465	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2004-12-31	2005-09-30	2006-09-30	-	-	2025-07-14
Virology Follow up Study in Subjects Previously Treated With Telaprevir	NCT00916474	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2009-06-30	2013-12-31	2014-12-31	-	-	2025-07-14
A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548	NCT05455502	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2022-07-13	2022-09-17	2023-09-17	-	-	2025-07-14
A Phase 1, First-in-human Study of VX-668	NCT05727800	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2023-02-08	2024-02-13	2025-02-13	-	-	2025-07-14
A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy Participants	NCT05818852	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2023-04-12	2023-06-28	2024-06-28	-	-	2025-07-14
A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants	NCT05518734	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2022-09-17	2023-03-07	2024-03-07	-	-	2025-07-14
Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study)	NCT02445053	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2015-04-30	2020-10-31	2021-10-31	-	-	2025-07-14
A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose	NCT06886269	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2025-03-21	2025-05-17	2026-05-17	-	-	2025-07-14
An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis	NCT01863238	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2013-05-31	2016-05-31	2017-05-31	-	-	2025-07-14
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease	NCT05477563	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2022-08-02	2027-06-09	2028-06-09	-	-	2025-07-14
Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation	NCT01161537	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2010-10-31	2013-02-28	2014-02-28	-	-	2025-07-14
A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using Wearable Technology in Cystic Fibrosis	NCT04923464	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2021-06-30	2021-12-20	2022-12-20	-	-	2025-07-14
A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)	NCT04599465	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2021-01-15	2022-07-14	2023-07-14	-	-	2025-07-14
Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis	NCT03278314	Vertex Pharmaceuticals Incorporated	user2@example.com	None	-	-	-	-	-	2025-07-14
Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection	NCT00623649	Vertex Pharmaceuticals Incorporated	user2@example.com	None	2007-11-30	2008-10-31	2009-10-31	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance